CAMBRIDGE, Mass., June 4, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will host an investor event focused on challenges and opportunities in the treatment of homozygous familial hypercholesterolemia (HoFH). The presentation will include a panel of physicians in the lipidology, cardiology and hepatology fields, as well as an HoFH patient. The event will be held on Tuesday, June 5, 2012, with the webcast scheduled to begin at 5:15 p.m. E.T.
The investor event will be webcast live and may be accessed through the "Investors" section of Aegerion's website, www.aegerion.com.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel, breakthrough therapeutics to treat debilitating and often fatal rare diseases. Aegerion is motivated by its commitment to patients first. We are also attentive to our core values of integrity, innovation, responsibility to healthcare providers, development of employees and always – scientific and clinical excellence.